Meta-analysis of randomized clinical trials comparing Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction

American Journal of Cardiology

Volumn 114, Issue 2, 2014, Pages 250-259

  Nairooz, Ramez ^a   Sardar, Partha ^b   Amin, Hossam ^c   Swaminathan, Rajesh V ^d   Kim, Luke K ^c   Chatterjee, Saurav ^e   Feldman, Dmitriy N ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRULOG; PRASUGREL;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONFERENCE PAPER; DATA BASE; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEAT PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW;

ANTICOAGULANTS; ANTITHROMBINS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84903196850     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.04.033     Document Type: Conference Paper

References (30)

1. A.M. Lincoff, N.S. Kleiman, K. Kottke-Marchant, E.S. Maierson, K. Maresh, K.E. Wolski, and E.J. Topol Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) Am Heart J 143 2002 847 853 (Pubitemid 34595343)
2. A.M. Lincoff, J.A. Bittl, R.A. Harrington, F. Feit, N.S. Kleiman, J.D. Jackman, I.J. Sarembock, D.J. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E.A. Cohen, A. Betriu, W. Desmet, D.J. Kereiakes, W. Rutsch, R.G. Wilcox, P.J. de Feyter, A. Vahanian, E.J. Topol REPLACE-2 Investigators Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863 (Pubitemid 37430344)
3. C.M. Gibson, D.A. Morrow, S.A. Murphy, T.M. Palabrica, L.K. Jennings, P.H. Stone, H.H. Lui, T. Bulle, N. Lakkis, R. Kovach, D.J. Cohen, P. Fish, C.H. McCabe, E. Braunwald TIMI Study Group A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial J Am Coll Cardiol 47 2006 2364 2373 (Pubitemid 43884775)
4. G.W. Stone, B.T. McLaurin, D.A. Cox, M.E. Bertrand, A.M. Lincoff, J.W. Moses, H.D. White, S.J. Pocock, J.H. Ware, F. Feit, A. Colombo, P.E. Aylward, A.R. Cequier, H. Darius, W. Desmet, R. Ebrahimi, M. Hamon, L.H. Rasmussen, H.J. Rupprecht, J. Hoekstra, R. Mehran, E.M. Ohman ACUITY Investigators Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216 (Pubitemid 44791162)
5. G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B.J. Gersh, S.J. Pocock, G. Dangas, S.C. Wong, A.J. Kirtane, H. Parise, R. Mehran HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230 (Pubitemid 351724451)
6. A. Kastrati, F.J. Neumann, S. Schulz, S. Massberg, R.A. Byrne, M. Ferenc, K.L. Laugwitz, J. Pache, I. Ott, J. Hausleiter, M. Seyfarth, M. Gick, D. Antoniucci, A. Schömig, P.B. Berger, J. Mehilli ISAR-REACT 4 Trial Investigators Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction N Engl J Med 365 2011 1980 1989
7. P.G. Steg, A. van 't Hof, C.W. Hamm, P. Clemmensen, F. Lapostolle, P. Coste, J. Ten Berg, P. Van Grunsven, G.J. Eggink, L. Nibbe, U. Zeymer, M. Campo dell' Orto, H. Nef, J. Steinmetz, L. Soulat, K. Huber, E.N. Deliargyris, D. Bernstein, D. Schuette, J. Prats, T. Clayton, S. Pocock, M. Hamon, P. Goldstein EUROMAX Investigators Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
8. M.S. Lee, H. Liao, T. Yang, J. Dhoot, J. Tobis, G. Fonarow, and E. Mahmud Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials Int J Cardiol 152 2011 369 374
9. D.P. Chew, D.L. Bhatt, W. Kimball, T.D. Henry, P. Berger, P.A. McCullough, F. Feit, J.A. Bittl, and A.M. Lincoff Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials Am J Cardiol 92 2003 919 923 (Pubitemid 37214802)
10. F.W. Verheugt, S.R. Steinhubl, M. Hamon, H. Darius, P.G. Steg, M. Valgimigli, S.P. Marso, S.V. Rao, A.H. Gershlick, A.M. Lincoff, R. Mehran, and G.W. Stone Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention JACC Cardiovasc Interv 4 2011 191 197
11. G. Ndrepepa, F.J. Neumann, E.N. Deliargyris, R. Mehran, J. Mehilli, M. Ferenc, S. Schulz, A. Schömig, A. Kastrati, and G.W. Stone Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials Circ Cardiovasc Interv 5 2012 705 712
12. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
13. Higgins JPT, Altman DG, Sterne JAC, eds. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). Available at: http://www.cochrane-handbook.org.
14. A.K. Rao, C. Pratt, A. Berke, A. Jaffe, I. Ockene, T.L. Schreiber, W.R. Bell, G. Knatterud, T.L. Robertson, and M.L. Terrin Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11 (Pubitemid 18029027)
15. D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, G.A. van Es, P.G. Steg, M.A. Morel, L. Mauri, P. Vranckx, E. McFadden, A. Lansky, M. Hamon, M.W. Krucoff, P.W. Serruys Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
16. G.W. Stone, H.D. White, E.M. Ohman, M.E. Bertrand, A.M. Lincoff, B.T. McLaurin, D.A. Cox, S.J. Pocock, J.H. Ware, F. Feit, A. Colombo, S.V. Manoukian, A.J. Lansky, R. Mehran, J.W. Moses Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial Lancet 369 2007 907 919 (Pubitemid 46400858)
17. J. Lefkovits, and E.J. Topol Direct thrombin inhibitors in cardiovascular medicine Circulation 90 1994 1522 1536 (Pubitemid 24284473)
18. D.E. Winchester, W.D. Brearley, X. Wen, K.E. Park, and A.A. Bavry Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines Clin Cardiol 35 2012 93 100
19. D.N. Feldman, R.V. Swaminathan, L.A. Kaltenbach, D.V. Baklanov, L.K. Kim, S.C. Wong, R.M. Minutello, J.C. Messenger, I. Moussa, K.N. Garratt, R.N. Piana, W.B. Hillegass, M.G. Cohen, I.C. Gilchrist, and S.V. Rao Adoption of radial access and comparison of outcomes to femoral access in percutaneous coronary intervention: an updated report from the National Cardiovascular Data Registry (2007-2012) Circulation 127 2013 2295 2306
20. A.K. Chhatriwalla, A.P. Amin, K.F. Kennedy, J.A. House, D.J. Cohen, S.V. Rao, J.C. Messenger, S.P. Marso National Cardiovascular Data Registry Association between bleeding events and in-hospital mortality after percutaneous coronary intervention JAMA 309 2013 1022 1029
21. D.M. Matic, D.G. Milasinovic, M.R. Asanin, I.B. Mrdovic, J.M. Marinkovic, N.I. Kocev, M.M. Marjanovic, N.M. Antonijevic, V.D. Vukcevic, L.Z. Savic, M.N. Zivkovic, Z.H. Mehmedbegovic, V.M. Dedovic, and G.R. Stankovic Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorization in patients undergoing primary cutaneous coronary intervention Heart 100 2014 146 152
22. S. Brugaletta, M. Sabate, V. Martin-Yuste, M. Masotti, Y. Shiratori, L. Alvarez-Contreras, A. Cequier, A. Iñiguez, A. Serra, R. Hernandez-Antolin, V. Mainar, M. Valgimigli, M. Tespili, P. den Heijer, A. Bethencourt, N. Vazquez, J. Gomez-Lara, B. Backx, and P.W. Serruys Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction: insights from the EXAMINATION trial Int J Cardiol 168 2013 2632 2636
23. G. De Luca, M.T. Dirksen, C. Spaulding, H. Kelbæk, M. Schalij, L. Thuesen, B. van der Hoeven, M.A. Vink, C. Kaiser, C. Musto, T. Chechi, G. Spaziani, L.S. Diaz de la Llera, V. Pasceri, E. Di Lorenzo, R. Violini, H. Suryapranata, G.W. Stone DESERT cooperation Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation Thromb Haemost 110 2013 826 833
24. G.D. Dangas, A. Caixeta, R. Mehran, H. Parise, A.J. Lansky, E. Cristea, B.R. Brodie, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, D. Dudek, M. Möeckel, G.W. Stone Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction Circulation 123 2011 1745 1756
25. G. Patti, G. Bárczi, D. Orlic, F. Mangiacapra, G. Colonna, V. Pasceri, E. Barbato, B. Merkely, I. Edes, M. Ostojic, W. Wijns, and G. Di Sciascio Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Myocardial Infarction) randomized study J Am Coll Cardiol 58 2011 1592 1599
26. P.A. Gurbel, K.P. Bliden, K. Butler, U.S. Tantry, T. Gesheff, C. Wei, R. Teng, M.J. Antonino, S.B. Patil, A. Karunakaran, D.J. Kereiakes, C. Parris, D. Purdy, V. Wilson, G.S. Ledley, and R.F. Storey Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
27. L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O.O. Braun, J.A. Jakubowski, A. Sugidachi, K.J. Winters, and A. Siegbahn Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
28. G. Parodi, R. Valenti, B. Bellandi, A. Migliorini, R. Marcucci, V. Comito, N. Carrabba, A. Santini, G.F. Gensini, R. Abbate, and D. Antoniucci Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
29. P.G. Steg, D.L. Bhatt, C.W. Hamm, G.W. Stone, C.M. Gibson, K.W. Mahaffey, S. Leonardi, T. Liu, S. Skerjanec, J.R. Day, R.S. Iwaoka, T.D. Stuckey, H.S. Gogia, L. Gruberg, W.J. French, H.D. White, R.A. Harrington for the CHAMPION Investigators Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data Lancet 382 2013 1981 1992
30. P. Sardar, R. Nairooz, S. Chatterjee, S. Mushiyev, G. Pekler, and F. Visco Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials J Thromb Thrombolysis 2013 10.1007/s11239-013-0998-5